Join our
Investor Newsletter

To receive Investor News as it is released please sign up

News Releases

Positive results from FractalDx study published

June 7, 2019
Download  full announcement Demonstrates ability to predict early rejection in kidney transplant Supports successful development of a predictive blood test for transplant patients Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease,

FDA grants Breakthrough Device designation to KidneyIntelX™

May 2, 2019
Download  full announcement Provides priority regulatory review of  AI-enabled diagnostic for fast-progressing kidney disease Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces that it has been granted Breakthrough Device

Acquisition of further interest in Renalytix AI plc

April 26, 2019
Download  full announcement   EKF Diagnostics Holdings  (AIM: EKF), the AIM quoted point-of-care business, notes the announcement by Renalytix AI plc (AIM: RENX) (“RenalytixAI”), that on 26 April 2019 EKF Diagnostics plc (“EKF”) acquired 100,074 ordinary RenalytixAI shares of £0.0025 each.

Director / PDMR Shareholding

April 26, 2019
Download  full announcement   The Company was informed that today, Christopher Mills, a non-executive director, completed the purchase of 3,168 ordinary shares of 0.25 pence each (“Ordinary Shares”) in the Company at a price of 112 pence per share. Following this purchase, Mr Mills is interested in

TR-1: Standard form for notification of major holdings

April 2, 2019
Download  full announcement NOTIFICATION OF MAJOR HOLDINGS  (to be sent to the relevant issuer  and  to the FCA in Microsoft Word format if possible) i   1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : Renalytix AI Plc 1b.
Displaying 171 - 180 of 203